Drugs / Multivirus-specific T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01070797 | Jan 2011 → May 2013 | Epstein-Barr virus infection, adenoviridae infectious disease, cytomegalovirus infection | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01570283 | Sep 2012 → Aug 2016 | viral infectious disease | AlloVir | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Multi-virus Specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01070797 ↗ |
| Action | Deplete | “This stimulation trains the donor T cells to kill cells that are infected with CMV, EBV, and adenovirus.” NCT01070797 ↗ |
| Modality | Cell therapy | “specially trained T cells” NCT01570283 ↗ |
| Route | Intravenous | “the donor's special cells will be thawed and injected into the patient's intravenous line.” NCT01070797 ↗ |